Frontiers in Immunology (Dec 2023)
Diagnostic value of kappa free light chain index in patients with primary progressive multiple sclerosis – a multicentre study
- Harald Hegen,
- Klaus Berek,
- Paola Cavalla,
- Mikael Christiansen,
- Andreja Emeršič,
- Massimiliano Di Filippo,
- Lorenzo Gaetani,
- Michaela Hassler,
- Cyra Leurs,
- Dejan Milosavljevic,
- Vincent van Pesch,
- Thor Petersen,
- Stefan Presslauer,
- Igal Rosenstein,
- Uroš Rot,
- Uroš Rot,
- Christine Schnabl,
- Charlotte Teunissen,
- Domizia Vecchio,
- Marco Vercellino,
- Florian Deisenhammer
Affiliations
- Harald Hegen
- Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria
- Klaus Berek
- Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria
- Paola Cavalla
- Multiple Sclerosis Center and Neurologia I U, Department of Neuroscience and Mental Health, AOU Città della Salute e della Scienza di Torino, Torino, Italy
- Mikael Christiansen
- Department of Clinical Biochemistry, Regional Hospital in Horsens, Horsens, Denmark
- Andreja Emeršič
- Department of Neurology, University Medical Centre Ljubljana, Ljubljana, Slovenia
- Massimiliano Di Filippo
- Section of Neurology, Department of Medicine and Surgery, University of Perugia, Perugia, Italy
- Lorenzo Gaetani
- Section of Neurology, Department of Medicine and Surgery, University of Perugia, Perugia, Italy
- Michaela Hassler
- FH Campus Wien, University of Applied Sciences, Vienna, Austria
- Cyra Leurs
- Department of Neurology and Neurophysiology, Amsterdam Neuroscience, Amsterdam UMC, Location VUMC, Amsterdam, Netherlands
- Dejan Milosavljevic
- FH Campus Wien, University of Applied Sciences, Vienna, Austria
- Vincent van Pesch
- Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium
- Thor Petersen
- Sygehus Sønderjylland, Department of Regional Health Research, University Hospital of Southern Denmark, Hadersleben, Denmark
- Stefan Presslauer
- 0Department of Neurology, Klinikum Ottakring, Vienna, Austria
- Igal Rosenstein
- 1Department of Clinical Neuroscience, Institute of Neuroscience and Physiology at Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
- Uroš Rot
- Department of Neurology, University Medical Centre Ljubljana, Ljubljana, Slovenia
- Uroš Rot
- 2Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
- Christine Schnabl
- FH Campus Wien, University of Applied Sciences, Vienna, Austria
- Charlotte Teunissen
- 3Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam UMC, Location Vrije Universiteit, Amsterdam Neuroscience, Amsterdam, Netherlands
- Domizia Vecchio
- 4Neurology Unit Department of Translational Medicine, Maggiore della Carità University Hospital, Novara, Italy
- Marco Vercellino
- Multiple Sclerosis Center and Neurologia I U, Department of Neuroscience and Mental Health, AOU Città della Salute e della Scienza di Torino, Torino, Italy
- Florian Deisenhammer
- Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria
- DOI
- https://doi.org/10.3389/fimmu.2023.1327947
- Journal volume & issue
-
Vol. 14
Abstract
BackgroundKappa free light chains (κ-FLC) in the cerebrospinal fluid (CSF) are an emerging biomarker in multiple sclerosis (MS).ObjectiveTo investigate whether κ-FLC index has similar diagnostic value in patients with primary progressive multiple sclerosis (PPMS) compared to oligoclonal bands (OCB).MethodsPatients with PPMS were recruited through 11 MS centres across 7 countries. κ-FLC were measured by immunonephelometry/-turbidimetry. OCB were determined by isoelectric focusing and immunofixation.ResultsA total of 174 patients (mean age of 52±11 years, 51% males) were included. κ-FLC index using a cut-off of 6.1 was positive in 161 (93%) and OCB in 153 (88%) patients.Conclusionκ-FLC index shows similar diagnostic sensitivity than OCB in PPMS.
Keywords
- cerebrospinal fluid
- kappa free light chain
- primary progressive
- multiple sclerosis
- diagnosis
- sensitivity
